• Determine the maximum tolerated dose (MTD) for each of 3 intermittent schedules and establish a recommended phase 2 dose of OSI-906 [ Time Frame: 2.5 years ] [ Designated as safety issue: No ]
  

• Safety profile, Pharmacokinetic profile, Pharmacodynamic relationships Preliminary antitumor activity [ Time Frame: 2.5 years ] [ Designated as safety issue: Yes ]
  

Multicenter, open-label, phase 1, cohort dose escalation. The study will open with S1 (OSI-906 QD Days 1-3 every 14 days). S2 (OSI-906 QD Days 1-5 every 14 days) will be initiated following observation of clinically significant related toxicity >/= grade 2 in S1 or after a review of preliminary safety and PK data from >/= 6 dose levels in S1 indicate that toxicity is acceptable and potential improvement in exposure may be achieved by an increased number of dosing days. S3 (OSI-906 QD Days 1-7 every 14 days) will occur upon observation of clinically significant related toxicity >/= grade 2 in S2 or after >/= 1 dose level in S2 has been examined. In each schedule, a single dose will be administered on each of the specified days followed by a drug-free period through to Day 14. A treatment period is defined as 14 days. Patients may continue to receive OSI-906 until one of the following occurs: disease progression, adverse event requiring withdrawal, failure to recover from toxicity despite a 14-day dosing interruption, medical or ethical reasons, patient request, or patient death.

Inclusion Criteria:

• Histologically or cytologically documented malignancy that is now advanced and/or metastatic and refractory to established forms of therapy or for which no effective therapy exists.
• History of allergic reaction attributed to a similar compound as study drug.
• Potassium, calcium, and magnesium within normal limits (WNL) for every measurement within 7 days of Day 1
• ANC >/= 1.5 x 10^9/L, PLT >/= 100 x 10^9/L;
• bilirubin </= 1.5 x upper limit of normal (ULN), AST and ALT </= 2.5 x ULN;
• creatinine </= 1.5 ULN
• Age >/= 18 years, ECOG PS 0-2,
• life expectancy >/= 12 weeks
• Prior chemotherapy is permitted provided that a minimum of 3 weeks has elapsed. Prior tyrosine kinase inhibitor therapy is permitted.
• Patients must have recovered from any treatment-related toxicities (with some exceptions) prior to registration.
• Prior hormonal therapy is permitted provided it is discontinued prior to registration (with the exception of prostate cancer patients who have been on hormone therapy for at least 3 months).
• Prior radiation therapy is permitted provided that patients have recovered from the toxic effects.
• A minimum of 21 days must have elapsed unless the radiotherapy was palliative and nonmyelosuppressive.
• Fasting glucose </= 125 mg/dL (7 mmol/L) at baseline
• History of any kind of stroke.
• History of any psychiatric condition that might impair the patient's ability to provide informed consent or participate.
• Accessible for repeat dosing and follow-up, including pharmacokinetic sampling.
• Patients must practice effective contraceptive measures throughout the study.
• Provide written informed consent.
• History of significant cardiac disease unless well controlled (includes 2nd/3rd degree heart block, ischemic heart disease, QTc > 450 msec, poorly controlled hypertension, and congestive heart failure of New York Heart Association (NYHA) Class II or worse

Exclusion Criteria:

• Any type of active seizure disorder.
• Concurrent anticancer therapy.
• Use of drugs with a risk of causing QT interval prolongation within 14 days prior to Day 1 and while on study.
• Use of glucocorticoids within 14 days prior to Day 1 and while on study.
• Previously diagnosed brain metastases.
• Documented history of diabetes mellitus.
• Active or uncontrolled infections of serious illnesses or medical conditions that could interfere with participation.
• Pregnant or breast-feeding females.